| Literature DB >> 31691873 |
Luca Nicosia1, Vanessa Figlia2, Rosario Mazzola2, Giuseppe Napoli2, Niccolò Giaj-Levra2, Francesco Ricchetti2, Michele Rigo2, Gianluigi Lunardi3, Davide Tomasini2,4, Marco L Bonù2,4, Stefanie Corradini5, Ruggero Ruggieri2, Filippo Alongi2,4.
Abstract
Stereotactic radiosurgery (SRS) is an effective treatment option for multiple brain metastases (BMs). Modern mono-isocentric techniques allow the delivery of multiple stereotactic courses, in the event of intracranial failure. Nevertheless, limited data on effectiveness and toxicity have been reported in comparison to WBRT. Aim of this retrospective matched-pair analysis was to compare patients affected by limited BMs treated with multiple SRS courses using a mono-isocentric, non-coplanar technique (HyperArc™, Varian Medical System) to upfront WBRT. One hundred and two patients accounting for 677 BMs were treated with HyperArc™. In case of further intracranial progression, 44 treatment courses of 201 metastases in 19 patients, were treated by subsequent HyperArc™ courses. This population was matched with 38 patients treated with WBRT. The median BMs number was 4 (range 2-10) for HyperArc™ and 5 (range 2-10) for WBRT. Overall survival (OS) and toxicity were evaluated. The median follow-up was 9 months (range 3-40 months). The median OS was not reached (range 5-22 months) for HyperArc™ patients and 8 months (range 3-40 months) for WBRT patients, while the 1-year OS was 77% and 34.6% for HyperArc™ and WBRT, respectively (p = 0.001; HR 4.77, 95% CI 1.62-14.00). There was one case of radionecrosis. HyperArc™ is an effective and safe technique for the treatment of multiple BMs. In selected cases of intracranial oligorecurrence, further subsequent courses can be safely delivered with the same technical approach. Moreover, in patients with a limited number of BMs, SRS showed an improved survival outcome when compared to WBRT.Entities:
Keywords: Brain metastases; HyperArc; Linac-based VMAT; Radiosurgery; Radiotherapy; Whole-brain radiotherapy
Mesh:
Year: 2019 PMID: 31691873 DOI: 10.1007/s10585-019-10004-3
Source DB: PubMed Journal: Clin Exp Metastasis ISSN: 0262-0898 Impact factor: 5.150